Life Sciences Needs Smarter Cold Chains: The Four Essentials

In response to its new research DHL Global Forwarding has signaled the need for a new generation of cold chains to be developed for the life sciences and healthcare industry in order to aid global health standards.The logistics firm’s infographic [see below] "The Smarter Cold Chain: Four essentials every company should adopt" highlights the challenges facing the healthcare industry as global demand for expensive structurally complex and temperature-sensitive biologics and specialty drugs grows.DHL's Infographic: Click to view. "Astounding developments in the life sciences industry coupled with globalization means there is an opportunity for better health, pain relief and cure from disease for many millions of people around the world," said Frank Appel, CEO of Deutsche Post DHL Group. "But getting the medication to patients in the right condition and achieving that goal requires a complex balancing of cost and risk. It emphasizes yet again the strong link between trade, logistics and the impact it has on improving people´s lives."[eventPDF]The firm maintains that pharmaceuticals are expensive and sensitive – and product integrity is paramount as ultimately someone’s health and even life may depend upon it. With global demand, particularly in emerging markets, growing hand in hand with ever stricter compliance from regulators, the industry faces a critical situation unless a new generation of cold chains are developed that can support growth aspirations and at the same time safeguard products. Global spending on healthcare is forecasted to reach around US$1.3 trillion by 2018 and the World Economic Forum estimates that by 2020 one third of all global health expenditure will be in emerging markets. Specialty drugs and biologics are one of the fastest growth areas with US spending on specialty drugs to quadruple to US$401.7 billion in 5 years, according to PricewaterhouseCoopers, with similar growth rates being projected for the rest of the world.These highly sensitive pharmaceuticals bring new complexity to the supply chain since they have specific condition tolerances and a high value. Annual per-patient treatment costs can be up to and above US$100,000, making a single consignment worth up to US$50 million. The distribution of these complex drugs and increased global demand is predicted to fuel approximately 60 percent growth in cold chain logistics reaching US$13.4 billion by 2020."Collapsed cold chains due to non-appropriate conditions can result in loss of a shipment worth hundreds of thousands of dollars. Over the longer term, this can lead to a damaged reputation, slumping sales, potential share value and even pose a risk to patients. These are high stakes and a smarter supply chain is necessary to overcome these challenges. As the life sciences and healthcare industry expands and transforms to meet the growing needs of the world, logistics providers need specialist investment in research and development as well to be able to offer the expertise needed to get medicine and equipment to the patients. In the simplest terms: better logistics can contribute to better healthcare," said Angelos Orfanos, President Life Sciences & Healthcare, DHL Customer Solutions & Innovation. Life-saving products need supply chain integrity According to the research, life sciences and healthcare companies that want to overcome the challenges of maintaining product integrity, regardless of the climactic conditions faced during global distribution, will find the need to build new generation of cold chains.Lisa Harrington, President of the lharrington group and Senior Research Fellow, Robert H. Smith School of Business, University of Maryland, and author of the research, recommends companies collaborate with logistics service providers that have the right infrastructure in place and can ensure consistent processes on a global level. "Securing product integrity requires the physical infrastructure to be designed and operated for life sciences products only," Harrington says. "It also requires having the right staff in place who fully understand end-to-end cold chain compliance. As providers of life-saving products, life sciences and healthcare companies have a responsibility to protect the lives of patients. Making sure their products arrive in perfect condition is critical. Partnering with the right logistics provider can ensure that."The infographic urges pharmaceutical companies to build high-performance partnerships to create and manage highly complex, next-generation supply chains. These partnerships need to be firmly based on a foundation of collaboration at both the strategic and tactical levels – all focused toward one common goal: serving the health of the patient. "In the current market situation, regulated by stricter compliance requirements, a robust packaging material is not enough to ensure a constant temperature range for a product," stresses Nigel Wing, Global Head Life Sciences & Healthcare, DHL Global Forwarding. "If not complemented by two critical essentials – a highly specialized and compliant network, and the right processes and people, packaging alone cannot do the job. Moving these goods across borders, especially in emerging markets, requires expertise and precision that currently only few can deliver. For example, DHL employs pharmacists around the world to oversee our operations, ensuring we comply with product and safety standards and helping us improve quality at every link in the supply chain." According to DHL’s report, smarter cold chains must be consistent and robust, incorporating ways of mitigating risk and loss, with strong contingency capabilities and proactive problem-resolution processes. Most importantly, they must be built on four key essentials:A highly specialized and compliant network tuned to moving products efficiently, while protecting their integrityGlobally consistent processes – policies and procedures that mitigate riskRisk-appropriate packaging – technology, cost appropriate, perfect handling Total cost strategy – includes assessing risk and the real cost of failure to the companySpecialized solutions for smarter supply chainsOn their way to the "next-generation" cold chain, pharmaceutical companies should implement a third essential into their supply chain, the report says. This tackles packaging and finding the right balance between costs and risk.Today, shippers can choose between passive and active solutions. When making their decision though, manufacturers must consider a wide range of factors, such as the value of the product, its temperature-management needs, regulatory compliance requirements, customer and market risk, as well as total cost. Finally, the fourth essential of a smarter supply chain is better cost management. According to the study, quite often, companies base their supply chain decisions on the direct costs visible to them, e.g. transportation or packaging costs. However, DHL explains that is just the tip of the iceberg. Potential indirect costs such as product losses, brand risks and regulatory issues are usually not accounted for due to the different siloes in an organization.Note: IQPC accepts no liability for content / activities on third party sites. Have Your Say Rate this feature and give us your feedback in the comments section below

Life Sciences Needs Smarter Cold Chains: The Four Essentials

Follow Us

Latest Webinars

How innovations in supply chain technology enable agility to move beyond visibility

Solve the labeling artwork puzzle

Digitizing your cold chain operations to improve patient outcomes

Recommended

Seven steps to ensure you are GDP-inspection ready

Bringing IDMP to life for patients: progress in 2019/2020

Three reasons to digitally transform Regulatory Affairs

A guideline for EUFMD implementation

Brexit risk to European medicine supply 'revised down'

New EU clinical trial guidelines lays down the principles for the two-step relea...

Record year forecasted for pharmaceutical air shipments

Pharma Logistics Compliance: 2018 Report

GDP compliance alerts sounded

2018 Trends to disrupt pharma supply chains

EU launches new GMP guidelines

EU transportation loophole could compromise drug quality

FIND CONTENT BY TYPE

Pharma Logistics COMMUNITY

ADVERTISE WITH US

JOIN THE Pharma Logistics COMMUNITY

Life Sciences Needs Smarter Cold Chains: The Four Essentials

Follow Us

Subscribe to our Free Newsletter

Latest Webinars

Recommended

FIND CONTENT BY TYPE

Pharma Logistics COMMUNITY

ADVERTISE WITH US

JOIN THE Pharma Logistics COMMUNITY